Tag - FULC

Developments

Stifel sees possible rebound year for biotech; top picks for 2022

In its biotech outlook, Stifel said that “on heels of weakness and negativity, 2022 may turn out to be a rebound year wherein biotech stocks – particularly decliners despite positive results and/or commercial...

January 5, 2022

Markets

Stifel starts coverage on 10 rare disease-focused companies

Stifel began coverage on 10 rare disease-focused companies, with seven “buy” and three “hold” ratings, noting that with an estimated 7,000-plus rare diseases – 95% of which lack approved therapy – these are early...

March 1, 2021

Markets

SVB Leerink starts Fulcrum Therapeutics at OP; PT $20

SVB Leerink initiated coverage of Fulcrum Therapeutics (NASDAQ:FULC) with an “outperform” rating and price target of $20 in 12 months. The stock closed at $11.62 on Aug. 9. Fulcrum is a clinical-stage biopharmaceutical...

August 12, 2019

Tag - FULC

Stifel sees possible rebound year for biotech; top picks for 2022

Stifel starts coverage on 10 rare disease-focused companies

SVB Leerink starts Fulcrum Therapeutics at OP; PT $20

General

More